Safety and efficacy of everolimus plus exemestane in postmenopausal women with treatment-refractory hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Analysis from EVEREXES Taiwan subset
Journal of Cancer Research and Practice（2023）
Key words
everolimus,breast cancer,postmenopausal women,treatment-refractory,receptor-positive
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined